Menü
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von StackerofWheat 

Vertex Pharmaceuticals Inc. diskutieren

Vertex Pharmaceuticals Inc.

WKN: 882807 / Symbol: VRTX / Name: Vertex / Aktie / Biotechnologie & medizinische Forschung / Large Cap /

435,40 €
-4,14 %

Einschätzung Buy
Rendite (%) -3,81 %
Kursziel 439,34
Veränderung
Endet am 02.08.25

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $480.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat

Einschätzung Buy
Rendite (%) -3,93 %
Kursziel 511,18
Veränderung
Endet am 02.08.25

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Guggenheim from $450.00 to $558.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,72 %
Kursziel 500,78
Veränderung
Endet am 05.08.25

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $550.00 price target on the stock, up previously from $508.00.
Ratings data for VRTX provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,72 %
Kursziel 464,36
Veränderung
Endet am 05.08.25

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JPMorgan Chase & Co. from $505.00 to $510.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat

Einschätzung Buy
Rendite (%) -0,39 %
Kursziel 501,77
Veränderung
Endet am 05.08.25

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $500.00 to $550.00. They now have an "outperform" rating on the stock.
Ratings data for VRTX provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 547,44
Veränderung
Endet am 05.08.25

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at HC Wainwright from $500.00 to $600.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat